Key Points
- EVP Rong Zhou sold 9,787 shares on Dec. 17 at an average price of $26.20 for $256,419.40, reducing his stake by 6.62% to 138,043 shares; the sale was disclosed in an SEC Form 4 filing.
- Recent quarter beat expectations: Amphastar reported $0.93 EPS (vs. $0.83 est.) and $191.84M revenue (vs. $186.90M), with a 15.43% net margin and 19.70% ROE.
- Market and analyst view: The stock trades around the mid-$20s (market cap ~$1.22B, P/E 11.7) and carries a consensus "Hold" rating with an average target price of $31.00.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 9,787 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total value of $256,419.40. Following the sale, the executive vice president owned 138,043 shares of the company's stock, valued at approximately $3,616,726.60. This represents a 6.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Amphastar Pharmaceuticals Stock Up 1.6%
Shares of AMPH stock opened at $26.50 on Friday. The stock's fifty day moving average price is $25.55 and its 200 day moving average price is $25.67. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $40.74. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 11.73, a price-to-earnings-growth ratio of 7.31 and a beta of 0.91. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.12 and a quick ratio of 2.21.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.93 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.10. The company had revenue of $191.84 million during the quarter, compared to analysts' expectations of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC raised its position in Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company's stock valued at $25,000 after acquiring an additional 737 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $26,000. Global Retirement Partners LLC boosted its holdings in Amphastar Pharmaceuticals by 219.0% during the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company's stock worth $27,000 after buying an additional 703 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Amphastar Pharmaceuticals by 192.8% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company's stock worth $29,000 after buying an additional 831 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its position in Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company's stock valued at $32,000 after buying an additional 1,338 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Bank of America upped their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research report on Tuesday, August 26th. Needham & Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Friday, November 7th. Weiss Ratings reissued a "hold (c)" rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 8th. Zacks Research cut Amphastar Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 14th. Finally, Barclays began coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They set an "equal weight" rating and a $30.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $31.00.
View Our Latest Stock Analysis on Amphastar Pharmaceuticals
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
